Blood Tests Before Starting Ozempic or Semaglutide: What You Need

Starting Ozempic or compounded semaglutide without baseline bloodwork is a bit like starting a road trip without knowing where you’re coming from. The labs you get before your first dose aren’t just a formality. They establish your personal starting point, screen for conditions that affect how you should be dosed, and catch contraindications before they become problems. Here’s exactly what to ask for, what each test is looking for, and how to make sure you’re starting treatment on solid footing.

Why Pre-Treatment Labs Are Non-Negotiable

Some telehealth providers skip the bloodwork and move straight to prescribing based on intake questionnaires alone. That approach isn’t inherently dangerous for every patient, but it leaves real gaps. Without baseline labs, your provider doesn’t know your kidney function, your liver enzyme levels, your starting A1c, or whether your thyroid is functioning normally. Any of those could affect dosing decisions, contraindicate the medication entirely, or change how aggressively your provider chooses to escalate your dose.

The previous article on what lab tests to expect while on GLP-1 medications covers ongoing monitoring during treatment. This article focuses specifically on the pre-treatment window, what to get before dose one and why each test is worth having.

The Core Pre-Treatment Panel

Most providers who follow evidence-based prescribing practices will order some version of the following tests before initiating semaglutide.

Comprehensive Metabolic Panel

The comprehensive metabolic panel, commonly called a CMP, is the workhorse of pre-treatment screening. It covers kidney function through creatinine and estimated glomerular filtration rate (eGFR), liver function through alanine aminotransferase (ALT) and aspartate aminotransferase (AST), blood glucose, electrolytes, and total protein.

Kidney function matters because semaglutide is cleared partly through renal pathways, and patients with significantly reduced kidney function may require closer monitoring or dose adjustments. Liver enzymes matter because elevated baseline levels, which can indicate fatty liver disease, alcoholic liver disease, or other hepatic conditions, help your provider interpret any enzyme changes that occur during treatment. Since GLP-1 medications consistently improve liver inflammation in most patients, having a baseline makes those improvements visible and meaningful.

Blood glucose from the CMP gives a snapshot of your current sugar level, which combined with A1c gives a more complete picture of your metabolic starting point.

Hemoglobin A1c

This is one of the most important pre-treatment tests for anyone starting semaglutide regardless of whether they have a diabetes diagnosis. HbA1c reflects your average blood sugar over the preceding two to three months and doesn’t require fasting, which makes it practical to obtain.

For patients without diabetes, a baseline A1c helps establish where you sit on the metabolic spectrum. An A1c between 5.7 and 6.4 percent indicates prediabetes, which is both a relevant clinical finding and often a factor in insurance coverage decisions. An A1c of 6.5 percent or higher suggests undiagnosed type 2 diabetes, which changes the clinical picture significantly and may affect which formulation of semaglutide is most appropriate.

For patients who already have a diabetes diagnosis, baseline A1c sets the target against which treatment response will be measured over time. The article on how Ozempic affects your A1c covers what changes to expect and at what timeframe once you start treatment.

Fasting Lipid Panel

A fasting lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Because GLP-1 medications consistently improve lipid profiles, particularly triglycerides and LDL, having a pre-treatment baseline allows you and your provider to quantify those improvements over time.

This matters practically for a few reasons. If your lipid numbers improve significantly during GLP-1 treatment, that information may support a conversation with your cardiologist or primary care provider about adjusting statin or other lipid-lowering therapy. Without a baseline, you can’t tell how much the medication contributed versus other changes in diet or lifestyle.

The article on GLP-1 medications and cholesterol details what the typical lipid response to GLP-1 treatment looks like and at what point in treatment those changes become measurable.

Thyroid Stimulating Hormone

TSH is ordered before starting GLP-1 medications for two related reasons. First, GLP-1 receptor agonists carry an FDA black box warning about thyroid C-cell tumors based on animal studies, and while the clinical relevance in humans remains uncertain, the warning does mean patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take these medications. A TSH result, combined with a thorough intake history, helps screen for relevant thyroid conditions.

Second, undiagnosed hypothyroidism is common and directly affects weight loss. A patient starting semaglutide with untreated hypothyroidism may find their response to the medication is blunted because hypothyroidism slows metabolism and makes weight loss significantly harder. Catching and treating this before starting GLP-1 therapy sets you up for better outcomes.

Fasting Insulin and HOMA-IR (Optional But Useful)

These two tests aren’t always included in standard pre-treatment panels, but they provide valuable information for patients with insulin resistance, PCOS, or prediabetes. Fasting insulin measures how much insulin your pancreas is producing in the fasted state, and HOMA-IR (homeostatic model assessment of insulin resistance) uses fasting glucose and fasting insulin together to estimate insulin sensitivity.

For patients with significant insulin resistance, this baseline helps track one of the key metabolic improvements that GLP-1 medications produce. It’s also useful context for understanding why weight loss may have been difficult before treatment and why semaglutide’s insulin-sensitizing effects are particularly relevant for their situation.

Additional Tests Based on Your Health History

Beyond the core panel, your provider may order additional tests based on what your intake history reveals.

If you have a history of kidney disease or are at elevated risk, a urine albumin-to-creatinine ratio (uACR) is worth obtaining alongside the CMP. This test detects early kidney damage that standard creatinine and eGFR measurements can miss, and it’s particularly relevant because GLP-1 medications have demonstrated kidney-protective effects that are worth tracking from a solid baseline.

If you have a history of pancreatitis or gallbladder disease, a lipase level and liver ultrasound may be appropriate before starting. GLP-1 medications are generally contraindicated in patients with a history of pancreatitis, and gallstone risk increases with rapid weight loss, making pre-treatment gallbladder assessment sensible for at-risk patients.

For women with PCOS or irregular cycles, adding fasting insulin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and free testosterone to the pre-treatment panel provides a hormonal baseline. The article on GLP-1 for PCOS covers how semaglutide affects hormonal patterns in this population, and having baseline hormone levels makes those changes trackable.

How to Get These Tests

If you have a primary care provider, the most straightforward approach is to request a pre-GLP-1 lab panel at your next visit or through a patient portal message. Most providers are familiar with these medications now and will order the appropriate tests without pushback.

If you’re using a telehealth provider for your GLP-1 prescription, ask directly whether baseline labs are required or recommended before your first dose. A provider who dismisses the question or says labs aren’t necessary is a provider worth questioning. Responsible prescribing in this context means understanding your baseline.

Some telehealth platforms, including those that specialize in GLP-1 medications, can order labs directly through partner lab services that allow you to get bloodwork drawn at a local facility without a separate in-person appointment. This removes the friction of coordinating between a telehealth provider and a primary care office.

If cost is a concern, community health centers and direct-to-consumer lab services like Quest Diagnostics and LabCorp offer the core panels at significantly lower out-of-pocket cost than hospital-based labs. A full pre-treatment panel through one of these services typically runs between $80 and $200 depending on which tests are included.

Starting treatment with a clear picture of your baseline metabolic health isn’t just good practice. It’s the foundation for understanding whether your treatment is actually working and making informed adjustments along the way. If you’re ready to take that first step, beginning with an assessment connects you with a provider who approaches prescribing with the thoroughness this medication deserves.

This information is for educational purposes and is not medical advice. Consult with a healthcare provider before starting any medication. Individual results may vary.